6JH0 Stock Chart & Stats
€0.90
-€0.07(-6.74%)
At close: 4:00 PM EDT
€0.90
-€0.07(-6.74%)
Day’s Range― - ―
52-Week Range€0.81 - €2.12
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€8.81M
Enterprise Value€11.67
Total Cash (Recent Filing)€17.96M
Total Debt (Recent Filing)€2.18M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Nov 05, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding9,858,383
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.29Price Target Upside376.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.94
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Narrowing Net LossesThe reduction in annual losses indicates improving cost discipline and operating control. While IN8bio remains far from profitability, sustaining this trend could extend its runway and improve the efficiency of investment in its clinical pipeline.
Improved Cash-Burn TrajectoryLower cash consumption than in prior periods suggests spending is becoming more controlled, which may slow funding needs as clinical programs advance. The improvement is meaningful, although cash generation remains negative and requires continued monitoring.
Modest LeverageLow debt relative to equity limits interest and refinancing pressure compared with a highly leveraged development-stage company. This provides some balance-sheet flexibility, allowing management to focus capital on research and clinical development rather than debt service.
Bears Say
No Product RevenueThe absence of product revenue means the company has no recurring commercial funding engine and remains dependent on clinical progress before meaningful monetization. This leaves results exposed to development delays, trial outcomes and regulatory execution risk.
Persistent Negative Cash FlowOngoing cash losses indicate that operations cannot currently fund research and development internally. Even with improved burn, the company must continue accessing capital or reduce activity, creating a durable constraint on pipeline investment and strategic flexibility.
Capital-Raising And Equity-Erosion RiskThe new at-the-market facility reinforces reliance on equity financing while the business remains pre-revenue. Additional share issuance can dilute existing holders, while cumulative losses and declining equity reduce the financial cushion supporting future development.
IN8bio News
6JH0 FAQ
What was IN8bio’s price range in the past 12 months?
IN8bio lowest stock price was €0.81 and its highest was €2.12 in the past 12 months.
What is IN8bio’s market cap?
IN8bio’s market cap is €8.81M.
When is IN8bio’s upcoming earnings report date?
IN8bio’s upcoming earnings report date is Nov 05, 2026 which is in 67 days.
How were IN8bio’s earnings last quarter?
IN8bio released its earnings results on Aug 06, 2026. The company reported -€0.217 earnings per share for the quarter, beating the consensus estimate of -€0.298 by €0.082.
Is IN8bio overvalued?
According to Wall Street analysts IN8bio’s price is currently Undervalued.
Does IN8bio pay dividends?
IN8bio does not currently pay dividends.
What is IN8bio’s EPS estimate?
IN8bio’s EPS estimate is -0.27.
How many shares outstanding does IN8bio have?
IN8bio has 9,858,383 shares outstanding.
What happened to IN8bio’s price movement after its last earnings report?
IN8bio reported an EPS of -€0.217 in its last earnings report, beating expectations of -€0.298. Following the earnings report the stock price went up 1.235%.
Which hedge fund is a major shareholder of IN8bio?
Currently, no hedge funds are holding shares in DE:6JH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IN8bio
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
6JH0 Stock 12 Month Forecast
Average Price Target
€4.29
▲(376.87% Upside)
Technical Analysis
Eterna Therapeutics
―
Quoin Pharmaceuticals
―
Xenetic Biosciences
―
―
Aprea Therapeutics
―